Research programme: menorrhagia therapeutics - Arbor Pharmaceuticals

Drug Profile

Research programme: menorrhagia therapeutics - Arbor Pharmaceuticals

Alternative Names: Tranexamic acid prodrug; XP 21510

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XenoPort
  • Class
  • Mechanism of Action Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Menorrhagia

Most Recent Events

  • 27 Mar 2012 Suspended - Preclinical for Menorrhagia in USA (PO)
  • 31 Jul 2009 XP 21510 is no longer licensed to Xanodyne Pharmaceuticals in USA
  • 31 Oct 2008 Preclinical development is ongoing for Menorrhagia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top